EHA 2022 | The clinical characteristics and prognosis of adults with Ph-ALL with TP53 aberrations
Jianxiang Wang
• 6 Jun 2022
Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China comments on several important clinical factors which are considered when assessing adults diagnosed with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Specifically, Dr Wang discusses how age, white blood cell count, karyotype, specific gene mutations, and the level of measurable residual disease (MRD) relate to patient prognosis and outcome measures following treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisor of AbbVie
